home / stock / tpst / tpst news

TPST News and Press, Tempest Therapeutics Inc. From 10/11/23

Stock Information
Company Name: Tempest Therapeutics Inc.
Stock Symbol: TPST
Market: NASDAQ
Website: tempesttx.com
Menu
TPST TPST Quote TPST Short TPST News TPST Articles TPST Message Board
Get TPST Alerts

News, Short Squeeze, Breakout and More Instantly...
TPST - 24/7 Market News Snapshot 11 Oct 2023

2023-10-11 09:55:22 ET DENVER, Colo., Oct. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Tempest Therapeutics (NASDAQ: TPST), Plug Power (NASDAQ: PLUG), Matinas BioPharma (AMEX: MTNB), Gaucho Group ...
TPST - Tempest Adopts Limited Duration Stockholder Rights Plan

BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the “Board&#...

TPST - Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2 study 30% confirmed ORR achieved in TPST-1120 arm compared to 13.3% for atezolizumab + bevac...

TPST - Tempest to Report New and Updated TPST-1120 Randomized Combination Study Data

2023-10-11 07:47:29 ET DENVER, Colo., Oct 11, 2023 ( www.247marketnews.com )- Tempest Therapeutics, Inc. (NASDAQ: TPST) stated, after yesterday’s market close, that it plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with a...
TPST - Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report new and updated data...

TPST - Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, announced today that executive vice president and chief medical...

TPST - Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Sam Whiting, M.D., Ph.D., chief medical of...
TPST - Tempest Therapeutics GAAP EPS of -$0.54 misses by $0.06

2023-08-11 04:27:51 ET Tempest Therapeutics press release ( NASDAQ: TPST ): Q2 GAAP EPS of -$0.54 misses by $0.06 . Tempest ended the second quarter with $17.6 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. For further detai...

TPST - Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, ...

TPST - Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495 anti-tumor response shown to be both immune dependent and immune independent Preclinic...
Previous 10 Next 10